Biocon share price
You have to be logged in to add this to Watchlist.- ₹356.40(-1.51%)February 12, 2025 15:55:59 PM IST
- NSE
- BSE
- Vol : 4.13M (NSE + BSE)Last 20 day avg : 4.74 M
Biocon is trading -1.51% lower at Rs 356.40 as compared to its last closing price. Biocon has been trading in the price range of 360.95 & 342.55. Biocon has given 5.87% in this year & 4.41% in the last 5 days. Biocon has TTM P/E ratio 54.34 as compared to the sector P/E of 26.23.There are 15 analysts who have initiated coverage on Biocon. There are 5 analysts who have given it a strong buy rating & 4 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 25.10 Crores in its last quarter.Listed peers of Biocon include Abbott India (-0.99%), Alkem Laboratories (-0.29%), Biocon (-1.51%).The Mutual Fund holding in Biocon was at 8.58% in 31 Dec 2024. The MF holding has increased from the last quarter. The FII holding in Biocon was at 5.66% in 31 Dec 2024. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Feb 12, 2025, 01:52 PM UTC
- Dividend YieldLower than industry0.13Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.35The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EExpensive P/E57.54Price-to-earnings ratio based on trailing 12-month earnings
- PEG RatioIndicates overvaluation5.07The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- BetaLow volatility0.73Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.82The debt-to-equity ratio, indicating a company's financial leverage.
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 3.35% from Rs 3953.70 crore to Rs 3821.40 crore, year-on-year- The company's profit declined by 96.20% year-on-year during the December quarter, dropping from Rs 660.00 crore to Rs 25.10 crore
- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
- R1
- 392.57
- R2
- 422.58
- R3
- 445.72
- S1
- 339.42
- S2
- 316.28
- S3
- 286.27
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Abbott India | Bullish | 28,849.30 | -0.99 | 61,240.75 | 52.72 | 17.12 | 1.38 | 0.99 |
| Alkem Laboratories | Bearish | 4,700.00 | -0.29 | 56,247.36 | 34.24 | 5.97 | 0.78 | 2.22 |
| Biocon | Neutral | 356.40 | -1.51 | 42,694.00 | 49.05 | 2.35 | 0.13 | 67.86 |
| Glenmark Pharmaceuticals | Bearish | 1,407.20 | -3.12 | 39,743.23 | - | 5.54 | 0.16 | 1.93 |
| IPCA Laboratories | Moderately Bearish | 1,420.20 | 0.07 | 36,057.57 | 58.30 | 6.04 | 0.27 | 9.80 |
- Promoter(s) holds a high stake in the company at 60.64%
- Mutual Funds holding has increased by 0.61 percentage points from previous quarter
- FIIs are invested in this company
- FIIs holding has decreased by 0.27 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-01-30 | Quarterly Results & Others |
| 2025-01-27 | Others |
| 2024-10-30 | Quarterly Results |
| 2024-08-08 | Quarterly Results |
| 2024-05-16 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE376G01013
- BSE Code532523
- NSE CodeBIOCON
Biocon is trading at 356.40 as on Wed Feb 12 2025 10:25:59. This is -1.51% lower as compared to its previous closing price of 361.85.
The market capitalization of Biocon is 42694.00 Cr as on Wed Feb 12 2025 10:25:59.
The average broker rating on Biocon is Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 4 analysts have given a buy rating
- 3 analysts have given a hold rating
- 2 analysts have given a sell rating
- 1 analysts have given a strong sell rating
The 52 wk high for Biocon is 404.60 whereas the 52 wk low is 244.40
Biocon can be analyzed on the following key metrics -
- TTM P/E: 54.34
- Sector P/E: 26.23
- Dividend Yield: 0.13%
- D/E ratio: -
Biocon reported a net profit of 1022.50 Cr in 2024.
The Mutual Fund Shareholding was 8.58% at the end of 31 Dec 2024.